Bayer AG
BAYN: XETR (DEU)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
€34.00 | Clmjjp | Bvff |
Bayer: Placing Under Review Based on Drug Trial Setback and Continued Glyphosate Litigation Risks
We are placing Bayer under review on the basis of the discontinuation of a key phase 3 asundexian drug trial and increasing glyphosate litigation concerns.